Abstract
Advances in transient expression technologies have allowed the production of milligram quantities of proteins within a matter of days using only small amounts (tens of grams) of plant tissue. Among the proteins that have been produced using this approach are the structural proteins of viruses which are capable of forming virus-like particles (VLPs). As such particulate structures are potent stimulators of the immune system, they are excellent vaccine candidates both in their own right and as carriers of additional immunogenic sequences. VLPs of varying complexity derived from a variety of animal viruses have been successfully transiently expressed in plants and their immunological properties assessed. Generally, the plant-produced VLPs were found to have the expected antigenicity and immunogenicity. In several cases, including an M2e-based influenza vaccine candidate, the plant-expressed VLPs have been shown to be capable of stimulating protective immunity. These findings raise the prospect that low-cost plant-produced vaccines could be developed for both veterinary and human use.
Keywords: Transient expression, virus-like particle, hepatitis B core antigen, human papillomavirus, bovine papillomavirus, bluetongue virus, foot-and-mouth disease virus, influenza virus, porcine respiratory and reproductive syndrome virus, protective immunity.
Current Pharmaceutical Design
Title:The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Volume: 19 Issue: 31
Author(s): Slavica Matic, George P. Lomonossoff, Konstantin G. Skryabin, Michael A. Eldarov, Nikolai V. Ravin, Oleg I. Kiselev, Edward P. Rybicki, Alta Hattingh, Ann Meyers, Emanuela Noris, Eva C. Thuenemann, Ivan N. Minkov, Gergana G. Zahmanova, Luis Enjuanes, Sonia Zuniga, Martina Becares, Michael Taliansky, Andrew J. Love and Paolo Lenzi
Affiliation:
Keywords: Transient expression, virus-like particle, hepatitis B core antigen, human papillomavirus, bovine papillomavirus, bluetongue virus, foot-and-mouth disease virus, influenza virus, porcine respiratory and reproductive syndrome virus, protective immunity.
Abstract: Advances in transient expression technologies have allowed the production of milligram quantities of proteins within a matter of days using only small amounts (tens of grams) of plant tissue. Among the proteins that have been produced using this approach are the structural proteins of viruses which are capable of forming virus-like particles (VLPs). As such particulate structures are potent stimulators of the immune system, they are excellent vaccine candidates both in their own right and as carriers of additional immunogenic sequences. VLPs of varying complexity derived from a variety of animal viruses have been successfully transiently expressed in plants and their immunological properties assessed. Generally, the plant-produced VLPs were found to have the expected antigenicity and immunogenicity. In several cases, including an M2e-based influenza vaccine candidate, the plant-expressed VLPs have been shown to be capable of stimulating protective immunity. These findings raise the prospect that low-cost plant-produced vaccines could be developed for both veterinary and human use.
Export Options
About this article
Cite this article as:
Matic Slavica, Lomonossoff P. George, Skryabin G. Konstantin, Eldarov A. Michael, Ravin V. Nikolai, Kiselev I. Oleg, Rybicki P. Edward, Hattingh Alta, Meyers Ann, Noris Emanuela, Thuenemann C. Eva, Minkov N. Ivan, Zahmanova G. Gergana, Enjuanes Luis, Zuniga Sonia, Becares Martina, Taliansky Michael, Love J. Andrew and Lenzi Paolo, The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants, Current Pharmaceutical Design 2013; 19 (31) . https://dx.doi.org/10.2174/1381612811319310011
DOI https://dx.doi.org/10.2174/1381612811319310011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Ex Vivo Models of HIV Sexual Transmission and Microbicide Development
Current HIV Research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Synthesis of (25R)-17α-Hydroxy-22-oxocholest-5-ene-3β,16β,26-triyl Triacetate: A One-Pot Approach to the Protected Aglycon Analogue of OSW-1
Letters in Organic Chemistry An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Recent Advances on Prediction of Human Papillomaviruses Risk Types
Current Drug Metabolism Nanoplatforms for Promoting Osteogenesis in Ovariectomy-Induced Osteoporosis in the Experimental Model
Current Nanomedicine Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets New Pyrano[2,3-d:6,5-d']dipyrimidine Derivatives-Synthesis, in vitro Cytotoxicity and Computational Studies
Anti-Cancer Agents in Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors
Current Bioactive Compounds The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Preparation of Cationic Lipid-coated Ultrasound Contrast Agents and Noninvasive Gene Transfection Via Ultrasound-targeted Microbubble Destruction
Current Pharmaceutical Design